About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker XENE · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 5, 2026A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy
NCT03796962 · Focal Epilepsy
XEN1101
XENE
Xenon Pharmaceuticals Inc.
Phase 2Active, not recruiting325Sep 2, 2021Registry ↗
Nov 2, 2026An Open-label Study of XEN1101 in Epilepsy
NCT05718817 · Focal Epilepsy, Tonic-Clonic Seizures
XEN1101
XENE
Xenon Pharmaceuticals Inc.
Phase 3Enrolling by invitation880Apr 2033Registry ↗
Nov 2, 2026A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
NCT05716100 · Focal Onset Seizures
XEN1101, Placebo
XENE
Xenon Pharmaceuticals Inc.
Phase 3Recruiting360Jan 2028Registry ↗
Nov 2, 2026A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
NCT05667142 · Primary Generalized Tonic-Clonic Seizures
XEN1101, Placebo
XENE
Xenon Pharmaceuticals Inc.
Phase 3Recruiting160Apr 2027Registry ↗
Oct 15, 2026A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
NCT07076407 · Major Depressive Disorder
Azetukalner, Placebo
XENE
Xenon Pharmaceuticals Inc.
Phase 3Active, not recruiting450May 2027Registry ↗
Oct 13, 2026An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)
NCT07217860 · Bipolar Depression, Bipolar I Disorder
Azetukalner
XENE
Xenon Pharmaceuticals Inc.
Phase 3Active, not recruiting400Jun 2029Registry ↗
Oct 13, 2026A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I o…
NCT07172516 · Bipolar Disorder, Bipolar Depression
Azetukalner, Placebo
XENE
Xenon Pharmaceuticals Inc.
Phase 3Active, not recruiting400Jun 2028Registry ↗
Oct 13, 2026An Open-Label Study of Azetukalner in Major Depressive Disorder
NCT06922110 · Major Depressive Disorder
Azetukalner
XENE
Xenon Pharmaceuticals Inc.
Phase 3Active, not recruiting460Jan 2027Registry ↗
Oct 13, 2026A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
NCT06775379 · Major Depressive Disorder
Azetukalner, Placebo
XENE
Xenon Pharmaceuticals Inc.
Phase 3Active, not recruiting450Oct 2026Registry ↗
Sep 21, 2026A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder
NCT05376150 · Major Depressive Disorder
XEN1101 10 mg, XEN1101 20 mg
XENE
Xenon Pharmaceuticals Inc.
Phase 2Completed168Sep 18, 2023Registry ↗
May 14, 2026A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
NCT05614063 · Focal Onset Seizures
XEN1101, Placebo
XENE
Xenon Pharmaceuticals Inc.
Phase 3Completed380Jan 12, 2026Registry ↗
Feb 14, 2025An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE
NCT04912856 · Epilepsy, Epilepsy in Children
XEN496
XENE
Xenon Pharmaceuticals Inc.
Phase 3Terminated8Nov 17, 2023Registry ↗
Aug 23, 2024XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy
NCT04639310 · Epilepsy, Epilepsy in Children
XEN496, Placebo
XENE
Xenon Pharmaceuticals Inc.
Phase 3Terminated8May 16, 2023Registry ↗
May 11, 2023Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of XEN1…
NCT03340220 · Healthy Volunteers
XPF-008, Microcrystalline Cellulose
XENE
Xenon Pharmaceuticals Inc.
Phase 1Completed130Nov 26, 2021Registry ↗
Jan 14, 2022Single-dose Mass Balance Recovery and Metabolite Profile and Identification of 14C-XEN1101
NCT04952467 · Healthy Volunteers
14C-XEN1101
XENE
Xenon Pharmaceuticals Inc.
Phase 1Completed6Oct 4, 2021Registry ↗
Jul 22, 2019Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901
NCT03467100 · Healthy Volunteers
XEN901, Inert Ingredients Oral Product
XENE
Xenon Pharmaceuticals Inc.
Phase 1Completed70Dec 19, 2018Registry ↗
Jan 22, 2019A Safety, Tolerability, Efficacy and Exposure Study of XEN801 Topical Gel
NCT02656043 · Acne Vulgaris
XPF-005, Placebo
XENE
Xenon Pharmaceuticals Inc.
Phase 1/2Completed213Feb 16, 2017Registry ↗
Sep 18, 2018Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Dos…
NCT03468725 · Healthy Male Volunteers
XPF-008, Microcrystalline Cellulose
XENE
Xenon Pharmaceuticals Inc.
Phase 1Completed20Jul 31, 2018Registry ↗

18 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 8:59 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances